STOCK TITAN
  1. Home
  2. News
  3. ISO

IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

About IsoPlexis
IsoPlexis is the Superhuman Cell company.

IsoPlexis’ systems uniquely identify a comprehensive range of multifunctional single cells, i.e. the superhero cells in the human body. These cells enable researchers to understand and predict disease progression, treatment resistance and therapeutic efficacy to advance all of human health.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at two-thirds of leading U.S. comprehensive cancer centers.

Investor Contact
investors@isoplexis.com 

Press Contact
press@isoplexis.com


Stock ISO logo
ISO

NASDAQ:ISO

ISO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ISO Latest News

Mar 21, 2023
Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company
Jan 12, 2023
IsoPlexis Reports Preliminary Full Year 2022 Revenue
Dec 21, 2022
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company
Dec 21, 2022
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company
Nov 10, 2022
IsoPlexis Reports Third Quarter 2022 Financial Results

ISO Stock Data

30.28M
18.21M
15.52%
76.92%
0.29%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Branford

About ISO

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.